Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887200364> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2887200364 abstract "AIM OF THE STUDY: Investigate the effect of Rosuvastatin on serum level of Vaspin and Visfatin in patients with CAD and determine the association between those adipokines and the severity of CAD. BACKGROUND: Statin treatment is considered one of the most effective strategies for the stabilization of atherosclerotic plaques and is related with enhancements in result in patients with coronary course diseases (CAD). Vaspin and Visfatin are adipokines involved in atherosclerosis progression. Objective: assess the impact of Rosuvastatin on serum level of Vaspin and Visfatin in patients with CAD and the relationship of those adipokines with seriousness of CAD. SETTING: Cardiology department, Tanta University Hospital, Egypt. METHODS: 80 patients who underwent coronary angiography due to symptoms of stable angina were enrolled in the study. 40 patients received Rosuvastatin 20 mg/day was compared to another 40 patients, as a control group, who refused statin treatment and preferred lifestyle modifications intervention. Main outcome measure: Clinical parameters, lipid profile, troponin I, high-sensitivity C-reactive protein (hs-CRP), Vaspin and Visfatin levels were assayed at the beginning and after 3 months. CAD severity was assessed by the Gensini score. RESULTS: Rosuvastatin administration considerably ameliorated most lipid parameters. Moreover, a significant increase of Vaspin and decrease of Visfatin concentrations (p<0.001) after Rosuvastatin treatment were observed (from 2.81 ± 0.74 ng/ml to 4.26 ± 0.76 ng/ml, from 4.62 ± 0.76 to 3.13 ± 0.98 respectively). There was a negative correlation between Vaspin and the Gensini score and positive correlation between Visfatin and Gensini score (r=-0.18 and r=0.19, p=0.05, respectively). CONCLUSION: Rousvastatin treatment reduces serum visfatin and increase serum vaspin levels in CAD patients. Those effects of Rousvastatin are of clinical importance." @default.
- W2887200364 created "2018-08-22" @default.
- W2887200364 creator A5022051535 @default.
- W2887200364 creator A5041696652 @default.
- W2887200364 creator A5046388388 @default.
- W2887200364 creator A5062478721 @default.
- W2887200364 date "2018-01-01" @default.
- W2887200364 modified "2023-09-28" @default.
- W2887200364 title "Effect of rosuvastatin on serum levels of vaspin and visfatin in patients with CAD" @default.
- W2887200364 doi "https://doi.org/10.4172/2368-0512.1000107" @default.
- W2887200364 hasPublicationYear "2018" @default.
- W2887200364 type Work @default.
- W2887200364 sameAs 2887200364 @default.
- W2887200364 citedByCount "0" @default.
- W2887200364 crossrefType "journal-article" @default.
- W2887200364 hasAuthorship W2887200364A5022051535 @default.
- W2887200364 hasAuthorship W2887200364A5041696652 @default.
- W2887200364 hasAuthorship W2887200364A5046388388 @default.
- W2887200364 hasAuthorship W2887200364A5062478721 @default.
- W2887200364 hasBestOaLocation W28872003641 @default.
- W2887200364 hasConcept C126322002 @default.
- W2887200364 hasConcept C134018914 @default.
- W2887200364 hasConcept C164705383 @default.
- W2887200364 hasConcept C194832188 @default.
- W2887200364 hasConcept C2776839432 @default.
- W2887200364 hasConcept C2778110834 @default.
- W2887200364 hasConcept C2780499067 @default.
- W2887200364 hasConcept C2780613262 @default.
- W2887200364 hasConcept C511355011 @default.
- W2887200364 hasConcept C71924100 @default.
- W2887200364 hasConcept C90924648 @default.
- W2887200364 hasConceptScore W2887200364C126322002 @default.
- W2887200364 hasConceptScore W2887200364C134018914 @default.
- W2887200364 hasConceptScore W2887200364C164705383 @default.
- W2887200364 hasConceptScore W2887200364C194832188 @default.
- W2887200364 hasConceptScore W2887200364C2776839432 @default.
- W2887200364 hasConceptScore W2887200364C2778110834 @default.
- W2887200364 hasConceptScore W2887200364C2780499067 @default.
- W2887200364 hasConceptScore W2887200364C2780613262 @default.
- W2887200364 hasConceptScore W2887200364C511355011 @default.
- W2887200364 hasConceptScore W2887200364C71924100 @default.
- W2887200364 hasConceptScore W2887200364C90924648 @default.
- W2887200364 hasIssue "02" @default.
- W2887200364 hasLocation W28872003641 @default.
- W2887200364 hasOpenAccess W2887200364 @default.
- W2887200364 hasPrimaryLocation W28872003641 @default.
- W2887200364 hasRelatedWork W1965393911 @default.
- W2887200364 hasRelatedWork W2005084305 @default.
- W2887200364 hasRelatedWork W2042646534 @default.
- W2887200364 hasRelatedWork W2073361868 @default.
- W2887200364 hasRelatedWork W2159962535 @default.
- W2887200364 hasRelatedWork W2161049361 @default.
- W2887200364 hasRelatedWork W2165052328 @default.
- W2887200364 hasRelatedWork W2508323870 @default.
- W2887200364 hasRelatedWork W2887200364 @default.
- W2887200364 hasRelatedWork W30481545 @default.
- W2887200364 hasVolume "05" @default.
- W2887200364 isParatext "false" @default.
- W2887200364 isRetracted "false" @default.
- W2887200364 magId "2887200364" @default.
- W2887200364 workType "article" @default.